Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of Icotinib as
neoadjuvant in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially
radical treated by surgery.